 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes HALOPERIDOL increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does HALOPERIDOL increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes HALOPERIDOL increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes HALOPERIDOL increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does HALOPERIDOL increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"haloperidol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: HALOPERIDOL: adverse_reactions: ADVERSE REACTIONS Cardiovascular Effects Tachycardia, hypotension, and hypertension have been reported. QT prolongation and/or ventricular arrhythmias have [0m
[31malso been reported, in addition to ECG pattern changes compatible with the polymorphous configuration of Torsades de pointes, and may occur more frequently with high doses and in predisposed patients [0m
[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. Cases of sudden and unexpected death have been reported in association with the administration of haloperidol. The nature of the evidence makes it impossible to [0m
[31mdetermine definitively what role, if any, haloperidol played in the outcome of the reported cases. The possibility that haloperidol caused death cannot, of course, be excluded, but it is to be kept in[0m
[31mmind that sudden and unexpected death may occur in psychotic patients when they go untreated or when they are treated with other antipsychotic drugs. HALOPERIDOL: adverse_reactions: CNS Effects [0m
[31mExtrapyramidal Symptoms [0m[1;31m([0m[31mEPS[0m[1;31m)[0m[31m EPS during the administration of haloperidol have been reported frequently, often during the first few days of treatment. EPS can be categorized generally as [0m
[31mParkinson-like symptoms, akathisia, or dystonia [0m[1;31m([0m[31mincluding opisthotonos and oculogyric crisis[0m[1;31m)[0m[31m. While all can occur at relatively low doses, they occur more frequently and with greater severity at [0m
[31mhigher doses. The symptoms may be controlled with dose reductions or administration of antiparkinson drugs such as benztropine mesylate, USP or trihexyphenidyl hydrochloride, USP. It should be noted [0m
[31mthat persistent EPS have been reported; the drug may have to be discontinued in such cases. Dystonia Class Effect Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in [0m
[31msusceptible individuals during the first few days of treatment. HALOPERIDOL: adverse_reactions: Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, [0m
[31mswallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at[0m
[31mhigher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. Withdrawal Emergent Neurological Signs Generally, patients [0m
[31mreceiving short-term therapy experience no problems with abrupt discontinuation of antipsychotic drugs. However, some patients on maintenance treatment experience transient dyskinetic signs after [0m
[31mabrupt withdrawal. In certain of these cases the dyskinetic movements are indistinguishable from the syndrome described below under â€œTardive Dyskinesiaâ€ except for duration.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: product_ndc         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: spl_id         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: precautions: No mutagenic potential of haloperidol was found in the Ames Salmonella microsomal activation assay. Negative or inconsistent positive findings have been obtained in [0m
[31min vitro and in vivo studies of effects of haloperidol on chromosome structure and number. The available cytogenetic evidence is considered too inconsistent to be conclusive at this time. [0m
[31mCarcinogenicity studies using oral haloperidol were conducted in Wistar rats [0m[1;31m([0m[31mdosed at up to [0m[1;31m5[0m[31m mg/kg daily for [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m and in Albino Swiss mice [0m[1;31m([0m[31mdosed at up to [0m[1;31m5[0m[31m mg/kg daily for [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m. In the [0m
[31mrat study, survival was less than optimal in all dose groups, reducing the number of rats at risk for developing tumors. However, although a relatively greater number of rats survived to the end of [0m
[31mthe study in high dose male and female groups, these animals did not have a greater incidence of tumors than control animals. HALOPERIDOL: precautions: Therefore, although not optimal, this study does[0m
[31msuggest the absence of a haloperidol related increase in the incidence of neoplasia in rats at doses up to [0m[1;31m20[0m[31m times the usual daily human dose for chronic or resistant patients. In female mice at [0m[1;31m5[0m[31m [0m
[31mand [0m[1;31m20[0m[31m times the highest initial daily dose for chronic or resistant patients, there was a statistically significant increase in mammary gland neoplasia and total tumor incidence; at [0m[1;31m20[0m[31m times the same[0m
[31mdaily dose there was a statistically significant increase in pituitary gland neoplasia. In male mice, no statistically significant differences in incidences of total tumors or specific tumor types [0m
[31mwere noted. Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers[0m
[31mare prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. HALOPERIDOL: precautions: [0m
[31mAlthough disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An [0m
[31mincrease in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown [0m
[31man association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. There are no well controlled [0m
[31mstudies with haloperidol in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of haloperidol along with other drugs which have suspected [0m
[31mteratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. HALOPERIDOL: precautions: Since such experience does not exclude the [0m
[31mpossibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. [0m
[31mInfants should not be nursed during drug treatment. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of haloperidol did not [0m
[31minclude sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not consistently identified [0m
[31mdifferences in responses between the elderly and younger patients. However, the prevalence of tardive dyskinesia appears to be highest among the elderly, especially elderly women [0m[1;31m([0m[31msee WARNINGS: [0m
[31mTardive Dyskinesia [0m[1;31m)[0m[31m. Also, the pharmacokinetics of haloperidol in geriatric patients generally warrants the use of lower doses [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs [0m
[31mare at an increased risk of death. Analyses of seventeen placebo-controlled trials [0m[1;31m([0m[31mmodal duration of [0m[1;31m10[0m[31m weeks[0m[1;31m)[0m[31m, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in [0m
[31mdrug-treated patients of between [0m[1;31m1.6[0m[31m to [0m[1;31m1.7[0m[31m times the risk of death in placebo-treated patients. Over the course of a typical [0m[1;31m10[0m[31m-week controlled trial, the rate of death in drug-treated patients was [0m
[31mabout [0m[1;31m4.5[0m[31m%, compared to a rate of about [0m[1;31m2.6[0m[31m% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular [0m[1;31m([0m[31me.g., heart failure, sudden death[0m[1;31m)[0m
[31mor infectious [0m[1;31m([0m[31me.g., pneumonia[0m[1;31m)[0m[31m in nature. HALOPERIDOL: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may [0m
[31mincrease mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some [0m[1;31mcharacteristic[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m of the patients is[0m
[31mnot clear. Haloperidol is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: warnings: WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are [0m
[31mat an increased risk of death. Haloperidol is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee BOXED WARNING [0m[1;31m)[0m[31m. Cardiovascular Effects Cases of sudden death, [0m
[31mQT-prolongation, and Torsades de pointes have been reported in patients receiving haloperidol. Higher than recommended doses of any formulation of haloperidol appear to be associated with a higher [0m
[31mrisk of QT-prolongation and Torsades de pointes. Although cases have been reported even in the absence of predisposing factors, particular caution is advised in treating patients with other [0m
[31mQT-prolonging conditions [0m[1;31m([0m[31mincluding electrolyte imbalance [0m[31m, drugs known to prolong QT, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome[0m[1;31m)[0m[31m. HALOPERIDOL: warnings: Tardive [0m
[31mDyskinesia A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome [0m
[31mappears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely[0m
[31mto develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. Both the risk of developing tardive dyskinesia and the likelihood that it[0m
[31mwill become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can [0m
[31mdevelop, although much less commonly, after relatively brief treatment periods at low doses. HALOPERIDOL: warnings: There is no known treatment for established cases of tardive dyskinesia, although [0m
[31mthe syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress [0m[1;31m([0m[31mor partially suppress[0m[1;31m)[0m[31m the signs and symptoms of the [0m
[31msyndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, [0m
[31mantipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who[0m
[31msuffer from a chronic illness that, [0m[1;31m1[0m[1;31m)[0m[31m is known to respond to antipsychotic drugs, and, [0m[1;31m2[0m[1;31m)[0m[31m for whom alternative, equally effective, but potentially less harmful treatments are not available or [0m
[31mappropriate.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: safe_handling_warning: OVERDOSAGE Manifestations In general, the symptoms of overdosage would be an exaggeration of known pharmacologic effects and adverse reactions, the most [0m
[31mprominent of which would be: [0m[1;31m1[0m[1;31m)[0m[31m severe extrapyramidal reactions, [0m[1;31m2[0m[1;31m)[0m[31m hypotension, or [0m[1;31m3[0m[1;31m)[0m[31m sedation. The patient would appear comatose with respiratory depression and hypotension which could be severe [0m
[31menough to produce a shock-like state. The extrapyramidal reaction would be manifest by muscular weakness or rigidity and a generalized or localized tremor as demonstrated by the akinetic or agitans [0m
[31mtypes respectively. With accidental overdosage, hypertension rather than hypotension occurred in a [0m[1;31m2[0m[31m year old child. The risk of ECG changes associated with Torsades de pointes should be considered. [0m
[1;31m([0m[31mFor further information regarding Torsades de pointes, please refer to ADVERSE REACTIONS . HALOPERIDOL: safe_handling_warning: [0m[1;31m)[0m[31m Treatment Gastric lavage or induction of emesis should be carried out [0m
[31mimmediately followed by administration of activated charcoal. Since there is no specific antidote, treatment is primarily supportive. A patent airway must be established by use of an oropharyngeal [0m
[31mairway or endotracheal tube or, in prolonged cases of coma, by tracheostomy. Respiratory depression may be counteracted by artificial respiration and mechanical respirators. Hypotension and [0m
[31mcirculatory collapse may be counteracted by use of intravenous fluids, plasma, or concentrated albumin, and vasopressor agents such as metaraminol, phenylephrine and norepinephrine. Epinephrine should[0m
[31mnot be used. In case of severe extrapyramidal reactions, antiparkinson medication should be administered. ECG and vital signs should be monitored especially for signs of Q-T prolongation or [0m
[31mdysrhythmias and monitoring should continue until the ECG is normal. HALOPERIDOL: safe_handling_warning: Severe arrhythmias should be treated with appropriate antiarrhythmic measures.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: package_ndc         [0m
[31mSOURCE:HALOPERIDOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Haloperidol has been reported to be associated with cardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with high doses and in predisposed[0m
[32mpatients. Cases of sudden and unexpected death have been reported in association with the administration of haloperidol, but the nature of the evidence makes it impossible to determine definitively [0m
[32mwhat role, if any, haloperidol played in these cases. The possibility that haloperidol caused death cannot be excluded, but sudden and unexpected death may also occur in psychotic patients when they [0m
[32mgo untreated or when they are treated with other antipsychotic drugs. There is no direct mention of myocardial infarction, but the cardiovascular risks associated with haloperidol, including sudden [0m
[32mdeath, suggest that there could be an increased risk of serious cardiac events such as myocardial infarction, especially in predisposed patients or those receiving high doses.[0m

[32mSOURCE: HALOPERIDOL label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mQT prolongation and/or ventricular arrhythmias[0m[32m...[0m[32m sudden and unexpected death[0m[32m...[0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Haloperidol has been reported to be associated with [0m
[34mcardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with high doses and in predisposed patients. Cases of sudden and unexpected death have been [0m
[34mreported in association with the administration of haloperidol, but the nature of the evidence makes it impossible to determine definitively what role, if any, haloperidol played in these cases. The [0m
[34mpossibility that haloperidol caused death cannot be excluded, but sudden and unexpected death may also occur in psychotic patients when they go untreated or when they are treated with other [0m
[34mantipsychotic drugs. There is no direct mention of myocardial infarction, but the cardiovascular risks associated with haloperidol, including sudden death, suggest that there could be an increased [0m
[34mrisk of serious cardiac events such as myocardial infarction, especially in predisposed patients or those receiving high doses.[0m

[34mSOURCE: HALOPERIDOL label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mQT prolongation and/or ventricular arrhythmias[0m[34m...[0m[34m sudden and unexpected death[0m[34m...[0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDA label for haloperidol reports associations with [0m
[32mcardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with high doses and in predisposed patients. While there is no direct mention of myocardial [0m
[32minfarction, the cardiovascular risks associated with haloperidol, including sudden death, suggest that there could be an increased risk of serious cardiac events such as myocardial infarction, [0m
[32mespecially in predisposed patients or those receiving high doses. However, the nature of the evidence makes it impossible to determine definitively what role, if any, haloperidol played in cases of [0m
[32msudden and unexpected death. Therefore, while there is an implication of increased risk, there is no conclusive evidence directly linking haloperidol to an increased risk of myocardial infarction.[0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does HALOPERIDOL increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if HALOPERIDOL increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the HALOPERIDOL label reports associations with cardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with high [0m
[32mdoses and in predisposed patients. Cases of sudden and unexpected death have been reported in association with the administration of haloperidol, but there is no direct mention of myocardial [0m
[32minfarction."[0m[32m,[0m
[32m      [0m[32m"The cardiovascular risks associated with haloperidol, including sudden death, suggest that there could be an increased risk of serious cardiac events such as myocardial infarction, especially [0m
[32min predisposed patients or those receiving high doses. However, the evidence is not definitive in establishing a causal relationship between haloperidol and myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Haloperidol is associated with cardiovascular effects that could suggest an increased risk of serious cardiac events such as myocardial infarction, especially in predisposed patients or[0m
[32mthose receiving high doses. However, there is no conclusive evidence directly linking haloperidol to an increased risk of myocardial infarction, as the FDA label does not specifically mention [0m
[32mmyocardial infarction in this context."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does HALOPERIDOL increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if HALOPERIDOL increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the HALOPERIDOL label reports associations with cardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with high [0m
[34mdoses and in predisposed patients. Cases of sudden and unexpected death have been reported in association with the administration of haloperidol, but there is no direct mention of myocardial [0m
[34minfarction."[0m[34m,[0m
[34m      [0m[34m"The cardiovascular risks associated with haloperidol, including sudden death, suggest that there could be an increased risk of serious cardiac events such as myocardial infarction, especially [0m
[34min predisposed patients or those receiving high doses. However, the evidence is not definitive in establishing a causal relationship between haloperidol and myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Haloperidol is associated with cardiovascular effects that could suggest an increased risk of serious cardiac events such as myocardial infarction, especially in predisposed patients or[0m
[34mthose receiving high doses. However, there is no conclusive evidence directly linking haloperidol to an increased risk of myocardial infarction, as the FDA label does not specifically mention [0m
[34mmyocardial infarction in this context."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does HALOPERIDOL increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if HALOPERIDOL increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that the HALOPERIDOL label reports associations with cardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with high doses [0m
[31mand in predisposed patients. Cases of sudden and unexpected death have been reported in association with the administration of haloperidol, but there is no direct mention of myocardial infarction.[0m
[1;31m3[0m[31m. The cardiovascular risks associated with haloperidol, including sudden death, suggest that there could be an increased risk of serious cardiac events such as myocardial infarction, especially in [0m
[31mpredisposed patients or those receiving high doses. However, the evidence is not definitive in establishing a causal relationship between haloperidol and myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: Haloperidol is associated with cardiovascular effects that could suggest an increased risk of serious cardiac events such as myocardial infarction, especially in predisposed [0m
[31mpatients or those receiving high doses. However, there is no conclusive evidence directly linking haloperidol to an increased risk of myocardial infarction, as the FDA label does not specifically [0m
[31mmention myocardial infarction in this context.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with the information given by FDAHandler and follows medical logic. The user correctly interprets the lack of direct evidence for a causal [0m
[32mrelationship between haloperidol and myocardial infarction, while also acknowledging the associated cardiovascular risks that could suggest a potential increased risk. The final answer appropriately [0m
[32mreflects the uncertainty and the lack of definitive evidence, which is in line with the guidelines provided. There are no specific flaws to identify in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with the information given by FDAHandler and follows medical logic. The user correctly interprets the lack of direct evidence for a causal [0m
[34mrelationship between haloperidol and myocardial infarction, while also acknowledging the associated cardiovascular risks that could suggest a potential increased risk. The final answer appropriately [0m
[34mreflects the uncertainty and the lack of definitive evidence, which is in line with the guidelines provided. There are no specific flaws to identify in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with the information given by FDAHandler and follows medical logic. The user correctly interprets the lack of direct evidence for a causal [0m
[31mrelationship between haloperidol and myocardial infarction, while also acknowledging the associated cardiovascular risks that could suggest a potential increased risk. The final answer appropriately [0m
[31mreflects the uncertainty and the lack of definitive evidence, which is in line with the guidelines provided. There are no specific flaws to identify in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mHaloperidol is associated with cardiovascular effects that could suggest an increased risk of serious cardiac events such as myocardial infarction, especially in predisposed patients or those [0m
[32mreceiving high doses. However, there is no conclusive evidence directly linking haloperidol to an increased risk of myocardial infarction, as the FDA label does not specifically mention myocardial [0m
[32minfarction in this context.[0m
